Pantoprazole Sodium Oral Suspension Recalled for Discoloration
Sun Pharmaceutical recalls Pantoprazole Sodium oral suspension nationwide due to product discoloration. Lot MHC1317A with approximately 14,064 units was distributed in the USA.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary recall for product discoloration without reported illnesses or injuries. No health hazard is indicated in the source; the recall addresses a quality issue.
Plain-English summary
Sun Pharmaceutical Industries Inc. is recalling Pantoprazole Sodium for Delayed-Release Oral Suspension (40 mg) nationwide due to product discoloration. The product is supplied as packets containing 40 mg pantoprazole suspended in apple juice or applesauce for oral administration.
The recall affects lot number MHC1317A (expiration 07/2023). Approximately 14,064 units (30 sachets per carton) were distributed nationwide in the USA. The product is distributed by Sun Pharmaceutical Industries, Inc. (Cranbury, NJ) and manufactured by Sun Pharmaceutical Industries Limited (Mohali, India).
This is a voluntary Class II recall initiated by the firm on July 25, 2022, and terminated on September 13, 2023.
The recalled product
- Product
- PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM)
- Brand
- PANTOPRAZOLE SODIUM
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Oral Suspension
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: MHC1317A
- Exp 07/2023
UPCs (1)
- 0362756071643
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · PANTOPRAZOLE SODIUM
- ModerateBaxter Recalls Pantoprazole Sodium Infusion Bags Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModeratePantoprazole Sodium Tablets Recalled for Discoloration Issues
FDA (Drugs) · 2026-04-29
- HighPantoprazole Sodium for Injection Recalled Due to Sterility Concern
FDA (Drugs) · 2023-09-20
- ModeratePantoprazole Sodium Tablets Recalled for CGMP Deviations and Discoloration
FDA (Drugs) · 2023-04-19
- High
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · discoloration
See all →- ModerateFresenius NaturaLyte Liquid Acid Concentrate Recalled for Discoloration
FDA (Devices) · 2026-09-09
- ModerateFresenius Citrasate Liquid Acid Concentrate Recalled for Discoloration
FDA (Devices) · 2026-09-09
- ModerateShilpa Medicare Recalls Discolored PEMRYDI RTU Injection Vials
FDA (Drugs) · 2026-08-26
- SevereShilpa Medicare Recalls Discolored Pemetrexed Injection Vials
FDA (Drugs) · 2026-08-26
- ModerateTavaborole topical solution recalled from three lots because of discoloration
FDA (Drugs) · 2025-10-22